Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Getein Biotech, Inc.

Getein Biotech, Inc. is a fully integrated in vitro diagnostic company that develops, manufactures and distributes an... read more Featured Products: More products

Download Mobile App





Getein Biotech Presents Sustainable Lab Solutions with Unlimited Possibilities at AACC 2022

By LabMedica International staff writers
Posted on 26 Jul 2022

Getein Biotech, Inc. More...

(Nanjing, China) is presenting its sustainable diagnostic solutions that offer unlimited possibilities for laboratories at the 2022 AACC Clinical Lab Expo.

AT AACC 2022, Getein will exhibit its range of POCT immunofluorescence quantitative analyzers, including the Getein1160, Getein1180, Getein1200 and Getein1600. These immunofluorescence quantitative analyzers automate the detection and quantification of markers for cardiovascular diseases, renal diseases, inflammation, fertility, diabetes mellitus, bone metabolism, tumor, and thyroid in biological samples. Getein is also showcasing the MAGICL6000 chemiluminescence immunoassay analyzer that automates the detection and quantification of markers for thyroid disease, inflammation, cardiac diseases, fertility, diabetes mellitus, bone metabolism, tumor, infectious disease, anemia, and immune globulin by analyzing human serum, plasma, whole blood and urine samples.

In addition, Getein will exhibit the fully automated CM-400 clinical chemistry analyzer for the quantitative analysis of chemical components in human serum, plasma, whole blood, urine, and cerebrospinal liquid samples. CM-400 is characterized by open reagents, discrete system, emergency priority, random access and an external computer. The analyzer consists of the main instrument and the computer with the main instrument composed of an optical system, reaction system, sample adding system, reagent adding system, cleaning system and mixing system, with an optional electrolyte module.

Getein is also highlighting the BHA-3000 and BHA-5000 automatic hematology analyzers that provide quantitative analysis of a patient's blood components at high speed with accuracy, alongside the XN06 semi-automated blood coagulation analyzer for testing four routine clotting test items, namely PT, TT, APTT and FIB. Getein will demonstrate its One Step Test for SARS-CoV-2 Antigen (Colloidal Gold) for the qualitative detection of SARS-CoV-2 antigens in human nasal swab samples. The test is suitable for medical laypersons as a self-test at home or at work. Getein provides a comprehensive range of COVID-19 testing solutions, including neutralizing antibody tests, antigen tests and IgM/IgG antibody tests. Getein also offers the Monkeypox Virus Real-time PCR Kit for the qualitative detection of MPV in serum or lesion exudate samples.
 

Related Links:
Getein Biotech, Inc. 


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Total Laboratory Automation Solution
SATLARS Mini T8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.